FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1499005405> ?p ?o ?g. }

• W1499005405 abstract "BackgroundIn light of the increased risk of progressive multifocal encephalopathy (PML) development under long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing remitting multiple sclerosis (RRMS), there is a clear need for alternative treatment options with comparable efficacy and reduced PML risk. One such option is fingolimod, a functional sphingosin-1-receptor antagonist that has been approved as first oral drug for treatment of active RRMS. However, the optimal switching design in terms of prevention of disease reoccurrence is still unknown. Moreover, potential additive effects of both drugs on immune functions, especially with regard to migration, have not yet been evaluated.Methods/designThis is an exploratory, open-label, monocentric, investigator-initiated clinical trial. Fifteen RRMS patients under stable treatment with natalizumab will receive one last natalizumab infusion followed by a wash-out period of 8 weeks before fingolimod treatment initiation for a period of 24 weeks. Disease activity under natalizumab and during switching will be closely monitored by assessment of relapse rate and disease severity as well as high-frequent high-resolution magnetic resonance imaging including quantitative diffusion tensor imaging. Immunological assays include longitudinal assessment of adhesion molecule expression, functional evaluation of the migratory capacity of immune cells in an in-vitro model of the blood–brain-barrier, and the quality of cellular antiviral immune responses.DiscussionOur trial represents the first detailed and longitudinal functional analysis of key immunological parameters in the process of switching from natalizumab and fingolimod, especially with regard to potential additive effects of both drugs on trafficking and immune surveillance. Moreover, our study will generate valuable information about even subtle disease exacerbations as consequence of natalizumab cessation, which will help to understand whether a switching protocol containing a wash-out period of 8 weeks before fingolimod treatment is appropriate in terms of disease stability." @default.
• W1499005405 created "2016-06-24" @default.
• W1499005405 creator A5008852999 @default.
• W1499005405 creator A5009943200 @default.
• W1499005405 creator A5015273008 @default.
• W1499005405 creator A5034872348 @default.
• W1499005405 creator A5037414415 @default.
• W1499005405 creator A5038373894 @default.
• W1499005405 creator A5057464377 @default.
• W1499005405 creator A5061814062 @default.
• W1499005405 creator A5061856360 @default.
• W1499005405 creator A5066648376 @default.
• W1499005405 creator A5067034255 @default.
• W1499005405 date "2015-06-23" @default.
• W1499005405 modified "2023-10-07" @default.
• W1499005405 title "Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)" @default.
• W1499005405 cites W1972758773 @default.
• W1499005405 cites W1975815652 @default.
• W1499005405 cites W1983092575 @default.
• W1499005405 cites W1983511886 @default.
• W1499005405 cites W1985359497 @default.
• W1499005405 cites W1986991730 @default.
• W1499005405 cites W1990742444 @default.
• W1499005405 cites W1993525641 @default.
• W1499005405 cites W1997159649 @default.
• W1499005405 cites W2002354029 @default.
• W1499005405 cites W2005024095 @default.
• W1499005405 cites W2006073149 @default.
• W1499005405 cites W2031060385 @default.
• W1499005405 cites W2039002352 @default.
• W1499005405 cites W2042551455 @default.
• W1499005405 cites W2043003871 @default.
• W1499005405 cites W2044022462 @default.
• W1499005405 cites W2049675062 @default.
• W1499005405 cites W2057903396 @default.
• W1499005405 cites W2062026431 @default.
• W1499005405 cites W2086344593 @default.
• W1499005405 cites W2092299335 @default.
• W1499005405 cites W2103758700 @default.
• W1499005405 cites W2104948944 @default.
• W1499005405 cites W2106467284 @default.
• W1499005405 cites W2111856386 @default.
• W1499005405 cites W2112165124 @default.
• W1499005405 cites W2113291839 @default.
• W1499005405 cites W2118058914 @default.
• W1499005405 cites W2122545833 @default.
• W1499005405 cites W2129586747 @default.
• W1499005405 cites W2142577589 @default.
• W1499005405 cites W2142729163 @default.
• W1499005405 cites W2145647479 @default.
• W1499005405 cites W2147502441 @default.
• W1499005405 cites W2151340435 @default.
• W1499005405 cites W2163280031 @default.
• W1499005405 cites W2164250102 @default.
• W1499005405 cites W2169082675 @default.
• W1499005405 cites W2171448646 @default.
• W1499005405 cites W2172026081 @default.
• W1499005405 doi "https://doi.org/10.1186/s12883-015-0354-9" @default.
• W1499005405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4477482" @default.
• W1499005405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26099927" @default.
• W1499005405 hasPublicationYear "2015" @default.
• W1499005405 type Work @default.
• W1499005405 sameAs 1499005405 @default.
• W1499005405 citedByCount "6" @default.
• W1499005405 countsByYear W14990054052016 @default.
• W1499005405 countsByYear W14990054052017 @default.
• W1499005405 countsByYear W14990054052019 @default.
• W1499005405 crossrefType "journal-article" @default.
• W1499005405 hasAuthorship W1499005405A5008852999 @default.
• W1499005405 hasAuthorship W1499005405A5009943200 @default.
• W1499005405 hasAuthorship W1499005405A5015273008 @default.
• W1499005405 hasAuthorship W1499005405A5034872348 @default.
• W1499005405 hasAuthorship W1499005405A5037414415 @default.
• W1499005405 hasAuthorship W1499005405A5038373894 @default.
• W1499005405 hasAuthorship W1499005405A5057464377 @default.
• W1499005405 hasAuthorship W1499005405A5061814062 @default.
• W1499005405 hasAuthorship W1499005405A5061856360 @default.
• W1499005405 hasAuthorship W1499005405A5066648376 @default.
• W1499005405 hasAuthorship W1499005405A5067034255 @default.
• W1499005405 hasBestOaLocation W14990054051 @default.
• W1499005405 hasConcept C126322002 @default.
• W1499005405 hasConcept C203014093 @default.
• W1499005405 hasConcept C2776036978 @default.
• W1499005405 hasConcept C2778577042 @default.
• W1499005405 hasConcept C2780640218 @default.
• W1499005405 hasConcept C2780644213 @default.
• W1499005405 hasConcept C2781004633 @default.
• W1499005405 hasConcept C71924100 @default.
• W1499005405 hasConcept C8891405 @default.
• W1499005405 hasConceptScore W1499005405C126322002 @default.
• W1499005405 hasConceptScore W1499005405C203014093 @default.
• W1499005405 hasConceptScore W1499005405C2776036978 @default.
• W1499005405 hasConceptScore W1499005405C2778577042 @default.
• W1499005405 hasConceptScore W1499005405C2780640218 @default.
• W1499005405 hasConceptScore W1499005405C2780644213 @default.
• W1499005405 hasConceptScore W1499005405C2781004633 @default.
• W1499005405 hasConceptScore W1499005405C71924100 @default.
• W1499005405 hasConceptScore W1499005405C8891405 @default.
• W1499005405 hasIssue "1" @default.
• W1499005405 hasLocation W14990054051 @default.

• next